A demonstration research of establishment and evaluation of breast hyperplasia disease clinical pathway.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TNRC-10000764

Enrollment

Unknown

Registered

2010-01-11

Start date

2009-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast hyperplasia disease

Interventions

Group A:Give ordinary treatment

Group B:Give the treatment in clinical pathway

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Conforming the diagnostic criteria for breast hyperplasia disease; 2. Conforming the TCM diagnostic criteria for breast hyperplasia disease; 3. At the age of 20-50 years old; 4. Course in 3 months above; 5. First treatment or has a history of breast hyperplasia disease without treatment nearly six months.

Exclusion criteria

Exclusion criteria: 1. Under the age of 20 years old, in adolescence have breast painful disease patients; 2. Above the age of 50 years old or menopausal women; 3. Pregnancy or breast feeding women; 4. With cardiovascular and cerebrovascular, liver, kidney and hematopoietic system of primary disease, insane patients; 5. With endocrine diseases caused by amenorrhoea patients; 6. With endocrine diseases of polycystic ovary, hyperprolactinemia, thyroid diseases; 7. With mastitis; 8. With breast cancer; 9. With breast fibromatosis; 10. had total hysterectomy or ovariectomy; 11. Have hormone therapy or acyeterion in half year; 12. Patients are not willing to join the test or not cooperate cure.

Design outcomes

Primary

Measure	Time frame
Curative effect;Cost;Degree of satisfaction;Waiting time;	—

Countries

China

Contacts

Public ContactXiaoyan Liu

yanlan_wu@yahoo.com.cn+86 13660796179

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026